Eosinophilia in a patient with ankylosing spondylitis treated with prolonged adalimumab only
- PMID: 35316919
- PMCID: PMC8924826
- DOI: 10.5114/aoms/146793
Eosinophilia in a patient with ankylosing spondylitis treated with prolonged adalimumab only
Conflict of interest statement
The authors declare no conflict of interest.
Similar articles
-
Efficiency of adalimumab, etanercept and infliximab in ankylosing spondylitis in clinical practice.Int J Clin Pharm. 2015 Oct;37(5):808-14. doi: 10.1007/s11096-015-0124-1. Epub 2015 Apr 25. Int J Clin Pharm. 2015. PMID: 25910480
-
Health-related quality of life outcomes in patients with active ankylosing spondylitis treated with adalimumab: results from a randomized controlled study.Arthritis Rheum. 2007 Aug 15;57(6):1050-7. doi: 10.1002/art.22887. Arthritis Rheum. 2007. PMID: 17665483 Clinical Trial.
-
Adalimumab reduces pain, fatigue, and stiffness in patients with ankylosing spondylitis: results from the adalimumab trial evaluating long-term safety and efficacy for ankylosing spondylitis (ATLAS).J Rheumatol. 2008 Jul;35(7):1346-53. Epub 2008 May 15. J Rheumatol. 2008. PMID: 18484692 Clinical Trial.
-
[Acute toxoplasmosis infection in a patient with ankylosing spondylitis treated with adalimumab: a case report].Reumatismo. 2010 Oct-Dec;62(4):283-5. doi: 10.4081/reumatismo.2010.283. Reumatismo. 2010. PMID: 21253622 Review. Italian.
-
Efficacy and safety of adalimumab treatment in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis.Expert Opin Drug Saf. 2011 Jul;10(4):655-73. doi: 10.1517/14740338.2011.581661. Epub 2011 May 10. Expert Opin Drug Saf. 2011. PMID: 21554150 Review.
Cited by
-
Epidemiological characteristics of ankylosing spondylitis in Guangxi Province of China from 2014 to 2021.Arch Med Sci. 2023 Jan 20;19(4):1049-1058. doi: 10.5114/aoms/159343. eCollection 2023. Arch Med Sci. 2023. PMID: 37560717 Free PMC article.
-
TNF-alpha Inhibitors Induced Eosinophilia: A Case Report of an Undervalued Side Effect of Such Biologicals.Endocr Metab Immune Disord Drug Targets. 2025;25(6):503-507. doi: 10.2174/0118715303309437240703114340. Endocr Metab Immune Disord Drug Targets. 2025. PMID: 39041261
References
LinkOut - more resources
Full Text Sources
Research Materials